Metabolic Syndrome

Core Definitions

• Cluster of cardiovascular risk factors associated with obesity and insulin resistance.
• Comprises insulin resistance, compensatory hyperinsulinemia, abdominal/visceral obesity, dyslipidemia (high triglycerides, low high-density lipoprotein), and hypertension.
• Serves as precursor to type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).
• Consensus pediatric definition precludes diagnosis in children younger than 10 years.
• Obesity component in children >10 years strictly defined by waist circumference, denoting intraabdominal fat accumulation.

Pathophysiology and Mechanisms

Altered Lipid Partitioning & Ectopic Fat

• Impact of obesity determined by specific depots of excess fat storage (lipid partitioning).
• "Adipose tissue expandability" hypothesis dictates subcutaneous adipose tissue capacity exceeded.
• Excess lipid shunts to ectopic tissues (liver, muscle).
• Intramyocellular lipid (IMCL) and intrahepatocellular lipid (IHCL) highly predictive of insulin resistance.
• Fatty acyl-CoA and diacylglycerol accumulate abnormally.
• Metabolites activate serine/threonine kinase cascade (c-jun N-terminal kinase 1, protein kinase C).
• Serine phosphorylation of insulin receptor substrate 1 (IRS-1) directly inhibits insulin signaling.

Hepatic and Skeletal Muscle Insulin Resistance

• Selective hepatic insulin resistance occurs.
• Impaired glucose homeostasis via FOXO1 pathway fails to suppress hepatic glucose output.
• Normal insulin-mediated hepatic de novo lipogenesis via SREBP-1c pathway maintained.
• Resultant excess triglyceride secretion, low HDL, and high small-dense LDL particles.
• Skeletal muscle exhibits reduced translocation of GLUT4 to cell membrane.
• Systemic glucose uptake markedly reduced.

Adipocytokine Dysregulation and Chronic Inflammation

• Adipose tissue functions as active endocrine organ.
• Macrophage infiltration of visceral adipose tissue elaborates inflammatory cytokines (TNF-alpha, interleukin-6).
• Inflammatory cytokines initiate proinflammatory milieu predating systemic insulin resistance.
• Circulating leptin levels rise significantly.
• Functional leptin resistance develops, limiting satiety signals.
• Adiponectin strictly reduced in obesity.
• Low adiponectin inversely related to visceral adiposity, IMCL, and IHCL.
• Loss of adiponectin removes crucial antiatherogenic and insulin-sensitizing effects.

Endothelial Dysfunction & Reactive Oxygen Species (ROS)

• Endothelial dysfunction represents earliest step in atherosclerosis development.
• Characterized by decreased nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS).
• Elevated free fatty acids (FFAs), TNF-alpha, IL-6, and ROS inhibit eNOS.
• Imbalance favors vasoconstricting factors (endothelin).
• Promotes smooth muscle proliferation, adhesion of inflammatory cells, atherosclerosis, and arterial wall stiffness.
• ROS generation increased via inflammatory cytokines, dysfunctional mitochondrial energetics, and glycation.

Risk Factors and Developmental Programming

Fetal Origins

• Small-for-gestational-age (SGA) and large-for-gestational-age (LGA) newborns carry inherently increased risk.
• Maternal gestational diabetes exposure independently impairs fetal beta-cell function and worsens insulin resistance.

Neuroendocrine Factors

• Hyperactive hypothalamus-pituitary-adrenal (HPA) axis elevates circulating cortisol.
• 11-beta-hydroxysteroid dehydrogenase type 1 converts inactive cortisone to active cortisol within visceral fat.
• Promotes visceral adiposity ("Cushing syndrome of the abdomen").
• Sleep deprivation directly predictive of prepubertal obesity.

Clinical Manifestations and Comorbidities

• Dermatologic: Acanthosis nigricans (marker of hyperinsulinemia).
• Hepatic: Nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH).
• Reproductive: Polycystic ovarian syndrome (PCOS) characterized by anovulation, clinical/biochemical hyperandrogenism.
• Respiratory: Obstructive sleep apnea (OSA) linked to endothelial dysfunction.
• Vascular: Hypertension, dyslipidemia (high triglycerides, small dense LDL, low HDL).
• Orthopedic: Slipped capital femoral epiphysis, Blount disease, limited mobility.

Diagnostic Criteria and Screening

• Exclude secondary dyslipidemias (hypothyroidism, nephrotic syndrome, cholestasis).
• Exclude classic endocrine obesity (Cushing syndrome, growth hormone deficiency, pseudohypoparathyroidism).

Screening Modalities

Management Strategies

Lifestyle and Dietary Interventions

• Foundation of metabolic syndrome therapy.
• Target weight loss of 7-10%.
• Dietary restriction of simple sugars (<25 g/day), sugar-sweetened beverages, and processed snacks.
• Saturated fat restricted to <7% of total calories.
• Dietary cholesterol restricted to <200 mg/day.
• Adoption of Dietary Approaches to Stop Hypertension (DASH) or Mediterranean-style diet.
• Minimum 60 minutes moderate-to-vigorous physical activity daily.
• Screen time strictly restricted to <2 hours daily.

Pharmacotherapy and Surgical Interventions